BPIQ-II is a linear imidazoloquinazoline that potently inhibits the tyrosine kinase activity of the epidermal growth factor receptor ( EGFR ; IC 50 =8 pM). It is selective for EGFR over an assortment of other tyrosine and serine/threonine kinases. Cellular studies indicate that BPIQ-II can enter cells and very selectively shut down EGF-stimulated signal transmission by binding competitively at the ATP site of EGFR .
Products | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Others | Products > Signaling Pathways > EGFR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.